TBPH - Theravance Biopharma Inc Net earnings per share (EPS TTM)

Theravance Biopharma margins are based on passive royalties from global bestsellers, ensuring a flawless cash flow. The fundamental EPS TTM metric on the GURU.Markets base chart reflects profit dynamics, with the current level sitting around 1.01. Predictable partner income minimizes costs, while the current strategy focuses on drug monetization and debt restructuring without mergers.
Theravance (TBPH) - metric breakdowns and financial figures

This indicator reflects the net income distributed per share over a rolling year, allowing for an assessment of the real return on capital while excluding seasonal fluctuations. Analysis of the 12-month rolling EPS value demonstrates the effectiveness of Theravance Biopharma (TBPH) in transitioning toward drug monetization and its success in debt restructuring, determining the fundamental value of the business during its sales optimization phase.